VBIO (Valion Bio) EBIT per Share: $-144.57 (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VBIO Valion Bio Inc VBIO
26 GF Score
Price $2.12
! 2 Warning Signs
View Full Analysis

What is Valion Bio EBIT per Share?

Valion Bio VBIO -5.15% 26 EBIT per Share is $-144.57 as of Jun. 2026. GuruFocus rates VBIO with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 1,169 Biotechnology companies, Valion Bio ranks worse than 85543.11% on this metric.

Valion Bio's EBIT per Share for the three months ended in Jun. 2026 was $-47.09. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $-144.57.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Valion Bio's EBIT per Share or its related term are showing as below:

VBIO's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.5
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Valion Bio's EBIT for the three months ended in Jun. 2026 was $-6.37 Mil.

Valion Bio  (NAS:VBIO) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Valion Bio EBIT per Share Related Terms

Valion Bio EBIT per Share Historical Data

* Premium members only.

The historical data trend for Valion Bio's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Valion Bio EBIT per Share Chart

Valion Bio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT per Share
Get a 7-Day Free Trial -81,161.13 -44,336.52 -4,418.05 -388.88 -169.77

Valion Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Mar26 Jun26
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -60.29 -47.52 -49.14 -48.35 -47.09
VBIO
26GF Score
Valion Bio Inc VBIO
EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Valion Bio EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Valion Bio's EBIT per Share for the fiscal year that ended in Dec. 2025 is calculated as

EBIT per Share(A: Dec. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-7.847/0.04622124
=-169.77

Valion Bio's EBIT per Share for the quarter that ended in Jun. 2026 is calculated as

EBIT per Share(Q: Jun. 2026 )
=EBIT/Shares Outstanding (Diluted Average)
=-6.366/0.13519988
=-47.09

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-144.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of $-144.57 mean?
Valion Bio (VBIO) has a EBIT per Share of $-144.57 as of Jun. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Valion Bio and its competitors. According to the industry distribution chart, Valion Bio ranks #999999 out of 1169 companies in the Biotechnology industry.
Is Valion Bio's EBIT per Share too high?
Valion Bio's current EBIT per Share is $-144.57. Based on the distribution chart, Valion Bio ranks #999999 out of 1169 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Valion Bio has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Valion Bio's EBIT per Share compare to CASIF and CMND?
According to the Biotechnology industry distribution chart, Valion Bio ranks #999999 out of 1169 companies for EBIT per Share. This places Valion Bio in the lower half of its industry. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,169 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Valion Bio and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valion Bio's current EBIT per Share is $-144.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valion Bio stock overvalued right now?
Valion Bio (VBIO) has a current EBIT per Share of $-144.57. The current EBIT per Share is $-144.57. Valion Bio's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Valion Bio (VBIO), the current EBIT per Share is $-144.57 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Valion Bio Business Description

Address 1305 East Houston Street, Suite 311, Building 1, San Antonio, TX, USA, 78205
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.
26GF Score

Get the complete analysis for VBIO

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.12
Price